Lord, Abbett & Co
ACRS icon

Lord, Abbett & Co’s Aclaris Therapeutics ACRS Stock Holding History

Lord, Abbett & Co’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-453,954
Closed -$3.11M – 513
2023
Q3 		$3.11M Buy
453,954
+55,602
+14% +$475K 0.01% 505
2023
Q2 		$4.13M Buy
+398,352
New +$3.6M 0.01% 497

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Lord, Abbett & Co's ACRS Position: Q4 2023 in Review

Lord, Abbett & Co sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 453,954 shares — an estimated $3.11M sold.

Lord, Abbett & Co first reported a position in ACRS in Q2 2023 and held it in 2 quarters. The position peaked at $4.13M in Q2 2023. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • Lord, Abbett & Co reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 453,954 Aclaris Therapeutics shares in Q4 2023, an estimated $3.11M.
  • Lord, Abbett & Co first reported a position in Aclaris Therapeutics in Q2 2023 and held it in 2 quarters.
  • Lord, Abbett & Co's Aclaris Therapeutics position peaked at $4.13M in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Lord, Abbett & Co's 13F filing for Q4 2023, filed 12 Feb 2024.